CRISPR-based Gene Editing

Global CRISPR-based Gene Editing Market to Reach US$11.0 Billion by 2030

The global market for CRISPR-based Gene Editing estimated at US$4.4 Billion in the year 2024, is expected to reach US$11.0 Billion by 2030, growing at a CAGR of 16.3% over the analysis period 2024-2030. CRISPR Kits & Reagents, one of the segments analyzed in the report, is expected to record a 18.3% CAGR and reach US$7.7 Billion by the end of the analysis period. Growth in the CRISPR Libraries segment is estimated at 12.3% CAGR over the analysis period.

The U.S. Market is Estimated at US$1.2 Billion While China is Forecast to Grow at 15.3% CAGR

The CRISPR-based Gene Editing market in the U.S. is estimated at US$1.2 Billion in the year 2024. China, the world`s second largest economy, is forecast to reach a projected market size of US$1.7 Billion by the year 2030 trailing a CAGR of 15.3% over the analysis period 2024-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 15.3% and 13.9% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 11.7% CAGR.

Global CRISPR-Based Gene Editing Market – Key Trends & Drivers Summarized

Why Is CRISPR-Based Gene Editing Transforming Biotechnology? Exploring the Breakthroughs in Precision Medicine

The global CRISPR-based gene editing market has witnessed rapid expansion, driven by advancements in genetic engineering, increased funding for biotechnology research, and the growing demand for precision medicine. CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats) technology has revolutionized the field of gene editing, enabling highly precise and efficient genetic modifications. The surge in gene therapy applications, aimed at treating genetic disorders such as sickle cell anemia, muscular dystrophy, and cystic fibrosis, has been a key driver of market growth. Additionally, CRISPR is playing an instrumental role in cancer immunotherapy, enabling the modification of immune cells to target tumors more effectively. With increasing interest in synthetic biology, CRISPR is also being utilized in the development of genetically engineered crops, microbial engineering for biofuel production, and disease-resistant livestock.

Which CRISPR-Based Applications Are Leading the Market? A Breakdown of Key Segments

The CRISPR-based gene editing market is segmented into therapeutic, agricultural, and industrial applications. The therapeutic segment, which includes gene therapy and regenerative medicine, dominates the market, as CRISPR is increasingly used to correct genetic mutations responsible for inherited diseases. Agricultural applications are also witnessing significant growth, with CRISPR being used to enhance crop yield, develop disease-resistant plants, and improve food security. The industrial biotechnology sector has also benefited from CRISPR, with applications in enzyme production, biofuel synthesis, and synthetic biology innovations. The emergence of CRISPR-based diagnostics, such as SHERLOCK and DETECTR, has further expanded the market’s scope by enabling rapid and cost-effective disease detection.

How Is Innovation Driving CRISPR-Based Gene Editing? The Role of AI, Nanotechnology & Bioinformatics

The CRISPR industry is evolving with the integration of artificial intelligence (AI), nanotechnology, and bioinformatics. AI-driven gene editing algorithms have enhanced precision, reducing the risk of off-target effects and improving editing efficiency. The development of next-generation Cas enzymes, such as Cas12 and Cas13, has expanded CRISPR’s capabilities beyond DNA editing to include RNA modifications. Nanotechnology-based CRISPR delivery systems, including lipid nanoparticles and viral vectors, are improving the efficiency and safety of gene-editing therapies. Additionally, advancements in bioinformatics tools are enabling researchers to model CRISPR interactions more accurately, optimizing gene-editing workflows. The rise of CRISPR-based epigenetic editing, which modifies gene expression without altering DNA sequences, has opened new possibilities for treating complex diseases.

What’s Driving the Growth of the CRISPR-Based Gene Editing Market? Key Market Influencers Explained

The growth in the CRISPR-based gene editing market is fueled by rising investment in biotechnology research, increasing applications in disease treatment, and advancements in delivery mechanisms. The expansion of gene therapy programs by pharmaceutical and biotech companies has strengthened the market’s commercial potential. Government funding initiatives and regulatory support for genome editing research have also accelerated innovation. The growing demand for personalized medicine, which leverages CRISPR to develop patient-specific treatments, has further boosted market growth. However, ethical concerns and regulatory scrutiny regarding human germline editing remain key challenges. With ongoing scientific advancements and broader acceptance of gene-editing applications, the CRISPR market is expected to witness transformative growth in the coming years.

SCOPE OF STUDY:

The report analyzes the CRISPR-based Gene Editing market in terms of units by the following Segments, and Geographic Regions/Countries:

Segments:
Products (CRISPR Kits & Reagents, CRISPR Libraries); Application (Biomedical Applications, Agricultural Applications); End-Use (Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use, Contract Research Organizations End-Use)

Geographic Regions/Countries:
World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 44 Featured) -
  • Beam Therapeutics
  • Caribou Biosciences
  • Cellectis
  • Colossal Biosciences
  • CRISPR Therapeutics
  • Editas Medicine
  • eGenesis
  • Graphite Bio
  • Inari Agriculture
  • Inscripta
  • Intellia Therapeutics
  • Mammoth Biosciences
  • Pairwise
  • Poseida Therapeutics
  • Precision BioSciences
  • Sangamo Therapeutics
  • SNIPR Biome
  • Synthego Corporation
  • Tropic Biosciences
  • Verve Therapeutics

TARIFF IMPACT FACTOR

Our new release incorporates impact of tariffs on geographical markets as we predict a shift in competitiveness of companies based on HQ country, manufacturing base, exports and imports (finished goods and OEM). This intricate and multifaceted market reality will impact competitors by artificially increasing the COGS, reducing profitability, reconfiguring supply chains, amongst other micro and macro market dynamics.

We are diligently following expert opinions of leading Chief Economists (14,949), Think Tanks (62), Trade & Industry bodies (171) worldwide, as they assess impact and address new market realities for their ecosystems. Experts and economists from every major country are tracked for their opinions on tariffs and how they will impact their countries.

We expect this chaos to play out over the next 2-3 months and a new world order is established with more clarity. We are tracking these developments on a real time basis.

As we release this report, U.S. Trade Representatives are pushing their counterparts in 183 countries for an early closure to bilateral tariff negotiations. Most of the major trading partners also have initiated trade agreements with other key trading nations, outside of those in the works with the United States. We are tracking such secondary fallouts as supply chains shift.

To our valued clients, we say, we have your back. We will present a simplified market reassessment by incorporating these changes!

APRIL 2025: NEGOTIATION PHASE

Our April release addresses the impact of tariffs on the overall global market and presents market adjustments by geography. Our trajectories are based on historic data and evolving market impacting factors.

JULY 2025 FINAL TARIFF RESET

Complimentary Update: Our clients will also receive a complimentary update in July after a final reset is announced between nations. The final updated version incorporates clearly defined Tariff Impact Analyses.

Reciprocal and Bilateral Trade & Tariff Impact Analyses:

USA
CHINA
MEXICO
CANADA
EU
JAPAN
INDIA
176 OTHER COUNTRIES.

Leading Economists - Our knowledge base tracks 14,949 economists including a select group of most influential Chief Economists of nations, think tanks, trade and industry bodies, big enterprises, and domain experts who are sharing views on the fallout of this unprecedented paradigm shift in the global econometric landscape. Most of our 16,491+ reports have incorporated this two-stage release schedule based on milestones.

Please note: Reports are sold as single-site single-user licenses. Electronic versions require 24-48 hours as each copy is customized to the client with digital controls and custom watermarks. The Publisher uses digital controls protecting against copying and printing is restricted to one full copy to be used at the same location.

The latest version of Adobe Acrobat Reader is required to view the report. Upon ordering an electronic version, the Publisher will provide a link to download the purchased report.

Prior to fulfillment of an order, the client will be required to sign a document detailing the purchase terms for a publication from this publisher.


I. METHODOLOGY
II. EXECUTIVE SUMMARY
1. MARKET OVERVIEW
Influencer Market Insights
Tariff Impact on Global Supply Chain Patterns
CRISPR-based Gene Editing – Global Key Competitors Percentage Market Share in 2025 (E)
Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2025 (E)
2. FOCUS ON SELECT PLAYERS
3. MARKET TRENDS & DRIVERS
Increasing Investment in Gene Therapy and Precision Medicine Spurs Market Growth for CRISPR-based Gene Editing
Surge in Biotechnology and Pharmaceutical Research Propels Demand for CRISPR as a Leading Gene Editing Tool
The Growing Need for Targeted and Personalized Treatments Expands Addressable Market for CRISPR Gene Editing Applications
Regulatory Advancements and Easing of Gene Editing Guidelines Accelerates the Commercialization of CRISPR-Based Therapies
The Expansion of Gene Therapy Clinical Trials Strengthens Business Case for CRISPR in Therapeutic Development
Rising Prevalence of Genetic Disorders and Chronic Diseases Drives Accelerated Adoption of CRISPR in Healthcare Solutions
Increasing Focus on Agricultural Biotechnology Strengthens the Case for CRISPR in Crop Improvement and Livestock Enhancement
Technological Advancements in CRISPR Delivery Mechanisms Propel Market Adoption in Both Clinical and Agricultural Sectors
The Shift Toward Sustainable Agriculture Drives Market Growth for CRISPR in Genetically Modified Crops with Enhanced Yield and Disease Resistance
Increased Investment in CRISPR Startups and Biotech Companies Spurs Innovation in Gene Editing Techniques
The Rise of CRISPR-Cas9-based Diagnostics and Point-of-Care Solutions Generates Demand for Gene Editing Technologies in Medical Devices
Public and Private Sector Collaborations and Funding Drive Growth in CRISPR-based Research and Development Projects
Regulatory and Ethical Challenges Surrounding Germline Editing Create Barriers to Market Growth in Certain Regions
Rising Demand for CRISPR in Cell and Gene Therapy Applications Expands Opportunities for Market Adoption in Regenerative Medicine
The Increasing Role of CRISPR in Infectious Disease Research and Treatment Drives New Opportunities in Global Health
Integration of CRISPR with AI and Machine Learning Strengthens the Business Case for Highly Targeted Gene Editing Solutions
Ethical Considerations and Public Perception of Gene Editing Technologies Throw the Spotlight on the Need for Responsible Innovation
Rising Demand for Non-invasive Gene Editing Solutions Spurs Growth in CRISPR-based Applications with Reduced Risk of Side Effects
The Need for Faster, More Accurate Genetic Research Drives Adoption of CRISPR in Academic and Commercial Research Laboratories
Advances in Genome Sequencing and Genomic Data Infrastructure Sustain Growth in the CRISPR-based Gene Editing Ecosystem
4. GLOBAL MARKET PERSPECTIVE
TABLE 1: World CRISPR-based Gene Editing Market Analysis of Annual Sales in US$ Million for Years 2015 through 2030
TABLE 2: World Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 3: World 6-Year Perspective for CRISPR-based Gene Editing by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2025 & 2030
TABLE 4: World Recent Past, Current & Future Analysis for CRISPR Kits & Reagents by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 5: World 6-Year Perspective for CRISPR Kits & Reagents by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 6: World Recent Past, Current & Future Analysis for CRISPR Libraries by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 7: World 6-Year Perspective for CRISPR Libraries by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 8: World Recent Past, Current & Future Analysis for Biomedical Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 9: World 6-Year Perspective for Biomedical Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 10: World Recent Past, Current & Future Analysis for Agricultural Applications by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 11: World 6-Year Perspective for Agricultural Applications by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 12: World Recent Past, Current & Future Analysis for Pharma & Biotech Companies End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 13: World 6-Year Perspective for Pharma & Biotech Companies End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 14: World Recent Past, Current & Future Analysis for Academic & Research Institutes End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 15: World 6-Year Perspective for Academic & Research Institutes End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
TABLE 16: World Recent Past, Current & Future Analysis for Contract Research Organizations End-Use by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 17: World 6-Year Perspective for Contract Research Organizations End-Use by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2025 & 2030
III. MARKET ANALYSIS
UNITED STATES
CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2025 (E)
TABLE 18: USA Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 19: USA 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 20: USA Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 21: USA 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 22: USA Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 23: USA 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
CANADA
TABLE 24: Canada Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 25: Canada 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 26: Canada Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 27: Canada 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 28: Canada Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 29: Canada 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
JAPAN
CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2025 (E)
TABLE 30: Japan Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 31: Japan 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 32: Japan Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 33: Japan 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 34: Japan Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 35: Japan 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
CHINA
CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2025 (E)
TABLE 36: China Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 37: China 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 38: China Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 39: China 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 40: China Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 41: China 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
EUROPE
CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2025 (E)
TABLE 42: Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2024 through 2030 and % CAGR
TABLE 43: Europe 6-Year Perspective for CRISPR-based Gene Editing by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2025 & 2030
TABLE 44: Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 45: Europe 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 46: Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 47: Europe 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 48: Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 49: Europe 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
FRANCE
CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2025 (E)
TABLE 50: France Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 51: France 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 52: France Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 53: France 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 54: France Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 55: France 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
GERMANY
CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2025 (E)
TABLE 56: Germany Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 57: Germany 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 58: Germany Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 59: Germany 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 60: Germany Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 61: Germany 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
ITALY
TABLE 62: Italy Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 63: Italy 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 64: Italy Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 65: Italy 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 66: Italy Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 67: Italy 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
UNITED KINGDOM
CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2025 (E)
TABLE 68: UK Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 69: UK 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 70: UK Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 71: UK 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 72: UK Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 73: UK 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
REST OF EUROPE
TABLE 74: Rest of Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 75: Rest of Europe 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 77: Rest of Europe 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 79: Rest of Europe 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
ASIA-PACIFIC
CRISPR-based Gene Editing Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2025 (E)
TABLE 80: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 81: Asia-Pacific 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 83: Asia-Pacific 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 85: Asia-Pacific 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
REST OF WORLD
TABLE 86: Rest of World Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Products - CRISPR Kits & Reagents and CRISPR Libraries - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 87: Rest of World 6-Year Perspective for CRISPR-based Gene Editing by Products - Percentage Breakdown of Value Sales for CRISPR Kits & Reagents and CRISPR Libraries for the Years 2025 & 2030
TABLE 88: Rest of World Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by Application - Biomedical Applications and Agricultural Applications - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 89: Rest of World 6-Year Perspective for CRISPR-based Gene Editing by Application - Percentage Breakdown of Value Sales for Biomedical Applications and Agricultural Applications for the Years 2025 & 2030
TABLE 90: Rest of World Recent Past, Current & Future Analysis for CRISPR-based Gene Editing by End-Use - Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use - Independent Analysis of Annual Sales in US$ Million for the Years 2024 through 2030 and % CAGR
TABLE 91: Rest of World 6-Year Perspective for CRISPR-based Gene Editing by End-Use - Percentage Breakdown of Value Sales for Pharma & Biotech Companies End-Use, Academic & Research Institutes End-Use and Contract Research Organizations End-Use for the Years 2025 & 2030
IV. COMPETITION

Download our eBook: How to Succeed Using Market Research

Learn how to effectively navigate the market research process to help guide your organization on the journey to success.

Download eBook
Cookie Settings